Talaris Therapeutics (TALS) Peer Comparison

$2.75

$-271.25 (-99.00%)

As on 19-Oct-2023 19:52EDT

Market cap

$120 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.3

Div. Yield

0 %

Edit

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Market cap ($ Mln)	120	11
Revenue ($ Mln)	--	--
Net Profit ($ Mln)	-57.66	-59.32
Net Margin (%)	-13,662.32	--
RoE (%)	-40.80	-131.83
Price to Earnings	--	--
Price-To-Book	0.28	0.91

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Operating Revenue	0.00	0.00
Cost of Revenue	0.00	0.00
Gross Profit	--	--
Operating Expenses	59.01	63.20
Operating Profit (EBIT)	-69.34	-63.20
Other Income	0.42	0.00
Profit before Tax	-62.78	-59.29
Provision for Tax	-0.50	0.03
Profit after Tax (Net Income)	-57.66	-59.32
Minority Interest	0.00	0.00
Consolidated Profit	-22.50	0.00

Liabilities ($ Mln)

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Shareholder's Funds	142.87	36.74
Minority Interest	0.00	0.00
Non-Current Liabilities	0.08	0.00
Current Liabilities	8.11	9.61
Total Liabilities	193.72	121.24

Assets ($ Mln)

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Non-Current Assets	0.01	3.85
Current Assets	151.05	42.50
Total Assets	193.72	-209.62
Total Debt*	0.63	1.43
Net Current Assets	0.00	0.00

Cashflow ($ Mln)

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Cash From Operating Activities	-60.86	-58.24
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	0.24	-0.58
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
ROCE (%)	-32.29	385.78
ROE (%)	-40.80	-131.83
ROA (%)	-22.27	-48.45
EBIT Margin (%)	--	--
Net Margin (%)	-13,662.32	--
Cash Profit Margin (%)	--	--

Growth Ratios

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Revenue Growth (%)	--	-1.00
EBIT Growth (%)	32.95	42.53
Net Profit Growth (%)	15.61	30.80
EPS Growth (%)	-725.99	32.35
Book Value Growth (%)	610.13	-57.22

Valuation Ratios

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Price / Earnings	-0.06	-1.66
Price / Book Value	0.02	-0.52
Dividend Yield (%)	--	--
EV/EBITDA	2.34	-0.80
Market Cap ($ Cr)	--	--

Solvency Ratios

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.00	0.04
Current Ratio	18.64	4.42
Quick Ratio	18.64	4.42
Interest Coverage	-7.93	-98.47

Operating Efficiency Ratios

	Talaris Therapeutics (TALS)	Frequency Therapeutics (FREQ)
Debtors to sales (%)	--	--
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	--	--
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly